30
Participants
Start Date
February 7, 2019
Primary Completion Date
October 3, 2022
Study Completion Date
October 3, 2022
INO-A002
Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
CELLECTRA® 2000
Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
Dengue Fever Antibodies (IgG)
To determine if the subject is Dengue seronegative at baseline
University of Pennsylvania, Philadelphia
Collaborators (1)
Inovio Pharmaceuticals
INDUSTRY
University of Pennsylvania
OTHER